

REPORT DOCUMENTATION PAGE

Form Approved
OMB NO. 0704-0188

Public Reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comment regarding this burden estimates or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave Blank)

2. REPORT DATE 8/2/04

3. REPORT TYPE AND DATES COVERED Final
2/26/01-~~5/23/04~~ May 31, 2004

4. TITLE AND SUBTITLE

Using phage lytic enzymes to kill pathogenic bacteria

5. FUNDING NUMBERS

DAAD19-01-1-0318

6. AUTHOR(S)

Vincent A. Fischetti

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)

Rockefeller University
1230 York Avenue
New York, NY 10021

8. PERFORMING ORGANIZATION
REPORT NUMBER

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)

U. S. Army Research Office
P.O. Box 12211
Research Triangle Park, NC 27709-2211

10. SPONSORING / MONITORING
AGENCY REPORT NUMBER

42293.1-LS

11. SUPPLEMENTARY NOTES

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision, unless so designated by other documentation.

12 a. DISTRIBUTION / AVAILABILITY STATEMENT

Approved for public release; distribution unlimited.

12 b. DISTRIBUTION CODE

13. ABSTRACT (Maximum 200 words)

Bacteriophage lytic enzymes are highly evolved molecules used by the phage to quickly destroy the bacterial cell wall to release bacteriophage progeny. We have exploited the rapid and lethal action of these enzymes to destroy pathogenic bacteria. These enzymes are specific for the species or strain from which they were produced, thus avoiding destruction of the surrounding normal commensal organisms found on mucosal surfaces. We now have enzymes that are specific for *S. pyogenes*, *S. pneumoniae*, and *B. anthracis* with enzyme for *S. aureus*, *E. faecalis*/*E. faecium* and group B streptococci in progress. Our results using any of the phage lytic enzymes show that in vitro, 10^7 bacteria can be sterilized seconds after enzyme contact. In animal model experiments, we were able to colonize mice with either streptococcal or pneumococcal species (orally or nasally) and remove them completely with phage enzymes delivered to these sites. In a septicemia model using *S. pneumoniae*, bacteria are reduced by >2-logs from the blood of infected animals with a single intravenous dose of enzyme. In subsequent experiments we plan to use constant infusion to clear organisms from blood. Thus, phage lytic enzymes are a new reagent that may be used to control pathogenic bacteria.

14. SUBJECT TERMS

20040810 056

15. NUMBER OF PAGES

16. PRICE CODE

17. SECURITY CLASSIFICATION
OR REPORT
UNCLASSIFIED

18. SECURITY CLASSIFICATION
ON THIS PAGE
UNCLASSIFIED

19. SECURITY CLASSIFICATION
OF ABSTRACT
UNCLASSIFIED

20. LIMITATION OF ABSTRACT
UL

NSN 7540-01-280-5500

Standard Form 298 (Rev.2-89)
Prescribed by ANSI Std. Z39-18
298-102

FINAL REPORT

Principal Investigator Name: Vincent A. Fischetti

Contract Number: DAAD19-01-1-0318

Title: Using Phage Lytic Enzymes to Destroy Pathogenic Bacteria

Phone: 212-327-8166

Fax: 212-326-7584

E-mail: vaf@mail.rockefeller.edu

Web: www.rockefeller.edu/vaf

Project Goals: We have developed a novel method to kill pathogenic bacteria safely and quickly. This method exploits the rapid yet specific activity of bacteriophage lytic enzymes to destroy pathogenic bacteria on contact. During the course of this grant we planned to develop enzymes that control *S. pyogenes*, *S. pneumoniae*, *S. aureus*, *E. faecalis* and group B streptococci. In preliminary experiments in vitro, 10 nanograms of the *S. pyogenes* phage enzyme could kill 10^7 streptococci in five seconds. In vivo, we were able to remove colonizing streptococci from the nasopharynx of heavily colonized mice. Our goal was to identify enzymes from a variety of phage active on several pathogens and used these enzymes to destroy these bacteria in blood of infected animals.

Final Report: During the tenure of this grant we were successful in identifying phage enzymes for a variety of pathogens. We now have developed enzymes that are specific for *S. pyogenes*, *S. pneumoniae*, *S. aureus*, *E. faecalis*/*E. faecium* and group B streptococci. Our results show that in vitro 10^7 bacteria can be reduced to sterility seconds after enzyme contact. In animal model experiments, we were able to colonize mice with either streptococcal or pneumococcal species (orally or nasally) and remove them completely with phage enzymes delivered to these sites using a single enzyme dose. In a septicemia model with *S. pneumoniae*, bacteria are reduced by >2-logs from the blood of infected animals with a single intravenous dose of enzyme. For the group B streptococcal enzyme we developed a vaginal model of colonization and found that a single dose of enzyme will remove colonizing group B strep two hours after treatment.

We found that two enzymes with different cell wall specificities work synergistically resulting in more efficient killing ability. In addition, when we searched for the presence of bacteria resistant to their respective enzymes, none were found in the enzymes we isolated, indicating that resistance is a rare event, rarer than antibiotic resistance.

Stability studies revealed that in general, these enzymes are quite stable and are able to withstand temperatures as high as 45°C for several hours and may be lyophilized for extended periods of time (18 months for the pneumococcal enzyme) and be fully active after reconstitution.

Pharmacokinetic experiments with the pneumococcal enzyme revealed that the half-life of this enzyme in blood is about 20 minutes, thus for this application multiple doses need to be administered or a constant i.v. infusion must be performed to eliminate all bacteria.

Thus, phage lytic enzymes are a new reagent that may be used in hospitals, nursing homes and the general population to control antibiotic resistant pathogenic bacteria in blood and on mucosal surfaces, offering a capability previously unavailable.

Published papers:

Loeffler, J., D. Nelson, and V.A. Fischetti. 2001. Rapid killing in of *S. pneumoniae* with a bacteriophage cell wall hydrolase. **Science.** **294**:2170-2172.

Loeffler, J. and V.A. Fischetti. 2003. Synergistic lethal effects of phage lytic enzymes with different activities on penicillin sensitive *S. pneumoniae*. **Antimicrob Agents Chemother.** **47**:375-7.

Nelson, D., Schuch, R., S. Zhu, D. Tscherne, and V.A. Fischetti. 2003. The genomic sequence of C1, the first streptococcal phage . **J. Bacteriol.** **185**:3325-3332.

Loeffler, J.M, S. Djurkovic and V.A. Fischetti. 2003. The phage lytic enzyme Cpl-1 as a novel antimicrobial for pneumococcal bacteremia and sepsis. **Infect. Immun.****71**:6199-204.

Yoong, P., R. Schuch, D. C. Nelson and V. A. Fischetti. 2004. Identification of a broadly active phage lytic enzyme with lethal activity against antibiotic resistant *Enterococcus faecalis* and *Enterococcus faecium*. **J Bacteriol.** **186**:4808-12.

Djurkovic, S., J. Loeffler, and V.A. Fischetti. 2004. Synergistic killing of *S. pneumoniae* with the bacteriophage lytic enzyme Cpl-1 and penicillin or gentamicin depends on the level or penicillin resistance. (Submitted).

Cheng, Q., D. Nelson, S. Zhu, and V.A. Fischetti. 2004. Removing group B streptococci colonizing the vagina and pharynx of mice with a bacteriophage lytic enzyme. (Submitted).